As Philips continues to work through its massive recall initiated 15 months ago impacting ventilators and sleep apnea devices, ResMed continues working to keep up with excess demand for CPAP ...

As Philips’ recall of many of its CPAP and BiPAP machines and other respiratory devices grew to include more machines and sparked tens of thousands of patient complaints, ResMed stepped up to fill ...

When Philips first began its massive recall of more than 5 million CPAP and BiPAP machines and other ventilators in mid-2021, its competitor ResMed swooped in to fill the void left behind—seemingly ...

Respiratory device makers ResMed (NYSE:RMD), and Philips (NYSE:PHG) traded lower on Friday after Eli Lilly (NYSE:LLY) said an FDA decision on a potential label expansion for its weight loss therapy ...

Mizuho said Wednesday that ResMed (NYSE:RMD) is now positioned to retain the more than $450M in US market share gains for "much longer" than anticipated, thanks to Philips’ (NYSE:PHG) recently ...

The Philips respiratory machine recall is a no-win situation for patients and doctors. But for the medical device giant’s longtime rivals and new competitors, business is looking up. “We think it will ...

Philips said it will scrap another 6,000 jobs – in addition to the 4,000 job cuts announced last October – in an effort to simplify its operating model in the wake of a massive recall that knocked off ...

Needham analyst Mike Matson reiterated a Buy rating on ResMed Inc. (NYSE:RMD) with a price target of $180. ResMed registered a street-beating performance in the first quarter, where revenue increased ...

Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...

Please provide your email address to receive an email when new articles are posted on . ResMed CPAP masks that contain magnets are being recalled due to possible magnetic interference with medical ...

Needham upgraded ResMed Inc RMD from a Hold to Buy rating with a price target of $180. The analysts Mike Matson, Joseph Conway, and David Saxon note that ResMed's shares are down 31% since the start ...